$400 million for genomics institute

In the largest act of US philanthropy for biomedical research, Eli and Edythe Broad have donated $400 million to the Broad Institute, a joint project between Harvard and the Massachusetts Institute of Technology. The gift builds on the $200 million with which the linkurl:Broads first funded the genomics institute;http://www.the-scientist.com/article/display/21404/ in 2003 and 2004. "We're now making a $600 million dollar bet in total that this will be the place where the world's greatest scien

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
In the largest act of US philanthropy for biomedical research, Eli and Edythe Broad have donated $400 million to the Broad Institute, a joint project between Harvard and the Massachusetts Institute of Technology. The gift builds on the $200 million with which the linkurl:Broads first funded the genomics institute;http://www.the-scientist.com/article/display/21404/ in 2003 and 2004. "We're now making a $600 million dollar bet in total that this will be the place where the world's greatest scientific discoveries will take place," Eli Broad said in a press conference today (September 4). The Broads' original donation, made just after the completion of the Human Genome Project in 2003, was a 10-year gift, meant to be used in its entirety within that time, said linkurl:Eric Lander,;http://www.the-scientist.com/article/display/20348/ founding director of the institute, in the press conference. The institution was meant to be an experiment in collaboration between different academic institutions, researchers across disciplines, and industry and academic researchers. With the additional funds announced today, "we shift the nature of that experiment," said Lander. Many of the institute's projects, including the linkurl:HapMap;http://www.the-scientist.com/article/display/23052/ project, the linkurl:RNAi Consortium,;http://www.the-scientist.com/article/display/52978/ and investigations of cancer genomics, will require several years to yield results. "This allows scientists to take on problems of a ten-year horizon" and beyond, Lander explained. Currently, the Broad is considered a part of MIT for administrative purposes, but is jointly governed by MIT and Harvard, who share overhead costs for the institute. It will continue to be governed by both institutions, but will transition out of MIT's purview to independent status as a nonprofit organization. Can the Broad's collaborative model be more widely adopted by other institutions? "I've given it a fair amount of thought, and it is my belief that the strength represented by Harvard, MIT, Whitehead, and the surrounding hospitals, would be very hard to reproduce anywhere else," linkurl:David Baltimore,;http://www.the-scientist.com/article/display/13725/ President Emeritus of the California Institute of Technology, said in the press conference. Correction (September 5): A previous version of this post incorrectly stated David Baltimore's position at CalTech. The Scientist regrets the error.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Alla Katsnelson

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours